Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DFTX Definium Therapeutics

Trading 02-12 14:47:09 EST

16.86

-0.49

-2.82%

High17.54	Low16.55	Vol643.67K
Open17.35	D1 Closing17.35	Amplitude5.71%
Mkt Cap1.66B	Tradable Cap1.54B	Total Shares98.51M
T/O10.94M	T/O Rate0.70%	Tradable Shares91.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":16.86,"timestamp":1770925620864,"preClose":17.35,"halted":0,"volume":643674,"delay":0,"changeRate":-0.028242074927954004,"floatShares":91334800,"shares":98509279,"eps":-1.975783,"marketStatus":"Trading","change":-0.49,"latestTime":"02-12 14:47:09 EST","open":17.35,"high":17.54,"low":16.55,"amount":10943671.969163999,"amplitude":0.057061,"askPrice":16.91,"askSize":2,"bidPrice":16.87,"bidSize":201,"shortable":3,"etf":0,"ttmEps":-1.975783,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":17.35,"preHourTrading":{"tag":"盘前","latestPrice":17.5,"preClose":17.35,"latestTime":"09:26 EST","volume":642,"amount":11303.117484,"timestamp":1770906380333,"change":0.15,"changeRate":0.008646,"amplitude":0.022478},"postHourTrading":{"tag":"盘后","latestPrice":17.2673,"preClose":17.35,"latestTime":"19:55 EST","volume":103181,"amount":1790110.9177,"timestamp":1770857727236,"change":-0.0827,"changeRate":-0.004767,"amplitude":0.014409},"volumeRatio":0.70041,"impliedVol":0.8515,"impliedVolPercentile":0.6842},"requestUrl":"/m/hq/s/DFTX","defaultTab":"news","newsList":[{"id":"2608281396","title":"LSD therapy biotech Definium sued for alleged trade secret theft","url":"https://stock-news.laohu8.com/highlight/detail?id=2608281396","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608281396?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:05","pubTimestamp":1770069917,"startTime":"0","endTime":"0","summary":"LSD therapy biotechDefinium sued for alleged trade secret theftBy Blake BrittainFeb 2 (Reuters) - A clinical-trial provider sued psychedelic therapy developer Definium Therapeutics DFTX.O on Monday in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nL6N3YY14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2608970328","title":"Definium Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2608970328","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608970328?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:00","pubTimestamp":1770066025,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc. has announced the issuance of inducement grants to two newly hired non-executive employees. The grants consist of options to purchase a total of 28,640 common shares, with an effective grant date of February 2, 2026. The options will vest over four years: 25% will vest on the first anniversary of the grant date, and the remaining 75% will vest in equal monthly increments over the subsequent three years. The exercise price for the options is set at the closing price of Definium’s common shares on the grant date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on February 02, 2026, and is solely responsi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL1lPJh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2607702998","title":"Definium Therapeutics Initiated at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2607702998","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607702998?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:34","pubTimestamp":1769805240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2026 15:34 ET (20:34 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2607010704","title":"Jefferies Initiates Coverage on Definium Therapeutics With Buy Rating, $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2607010704","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607010704?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:28","pubTimestamp":1769776130,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, Inc. (DFTX) has an average rating of Buy and mean price target of $31.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DFTX"],"gpt_icon":0},{"id":"2607592019","title":"Definium Therapeutics initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2607592019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607592019?lang=en_us&edition=fundamental","pubTime":"2026-01-30 18:15","pubTimestamp":1769768135,"startTime":"0","endTime":"0","summary":"Jefferies analyst Andrew Tsai last night initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $30 price target The firm says a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-initiated-with-a-buy-at-jefferies-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-initiated-with-a-buy-at-jefferies-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2607094715","title":"U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner Enterprises","url":"https://stock-news.laohu8.com/highlight/detail?id=2607094715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607094715?lang=en_us&edition=fundamental","pubTime":"2026-01-30 15:45","pubTimestamp":1769759121,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner EnterprisesJan 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, incl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL8N3YV0KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DDOG","DECK","CEG","CRS","AX","ALNY","MO","CVSA","DOW","BX","AAPD","CMCSA","AAPU","AMP","DT","BIIB","CRNX","CHRW","BFH","DUK","APLY","ATGE","AAPL","BC","ALGM","ARE","BL","ATEC","DOCS","AOS","BBT","DKNG","AAPW","CACC","APH","BK4533","MACW.SI","DOV","DFTX","CAT","CNX","AAPX","AAPB","APPF","CFR","AJG","NLY","AAPY","V","CALX","ABT"],"gpt_icon":1},{"id":"2607065034","title":"Definium Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Roger Adsett","url":"https://stock-news.laohu8.com/highlight/detail?id=2607065034","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607065034?lang=en_us&edition=fundamental","pubTime":"2026-01-30 09:34","pubTimestamp":1769736867,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Roger Adsett as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDLbx6gBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Definium Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Roger Adsett","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2607279035","title":"Definium Therapeutics appoints Roger Adsett to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2607279035","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607279035?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:36","pubTimestamp":1769697398,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) announced the appointment of Roger Adsett to its Board of Directors. Adsett currently serves as COO of Insmed (INSM). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-appoints-roger-adsett-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-appoints-roger-adsett-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0109394709.USD","DFTX","LU0889565916.HKD","LU0053671581.USD","INSM","BK4007","LU0320765992.SGD"],"gpt_icon":0},{"id":"2607087114","title":"Definium Therapeutics Expands Board, Appoints New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2607087114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607087114?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:01","pubTimestamp":1769691672,"startTime":"0","endTime":"0","summary":"Definium Therapeutics ( ($DFTX) ) has issued an announcement. On January 28, 2026, Definium Therapeutics, Inc. expanded its board of directors from...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-expands-board-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-expands-board-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2607208449","title":"BRIEF-Definium Therapeutics Appoints Roger Adsett To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2607208449","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607208449?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:21","pubTimestamp":1769689309,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Appoints Roger Adsett To Board Of DirectorsJan 29 (Reuters) - Definium Therapeutics Inc DFTX.O:DEFINIUM THERAPEUTICS APPOINTS ROGER ADSETT TO BOARD OF DIRECTORSSource text: ID:nBwhbDLGaFurther company coverage: DFTX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUA5HZHZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2607081683","title":"Definium Therapeutics Appoints Roger Adsett to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2607081683","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607081683?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:00","pubTimestamp":1769688052,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc. has appointed Roger Adsett to its Board of Directors. Adsett brings over two decades of experience in the biopharmaceutical industry, specializing in drug launches and building global commercial organizations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL4r2nJc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2606225023","title":"Definium Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2606225023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606225023?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:01","pubTimestamp":1769461272,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc. has granted options to purchase a total of 88,850 common shares to three newly hired non-executive employees. The options were granted with effective dates of January 12 and January 26, 2025, at an exercise price equal to the closing price of Definium's common shares on the respective grant dates. The options will vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal monthly increments over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on January 26, 2026, an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLjl8NF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2605400196","title":"Definium Therapeutics price target raised to $36 from $20 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605400196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605400196?lang=en_us&edition=fundamental","pubTime":"2026-01-24 03:36","pubTimestamp":1769196999,"startTime":"0","endTime":"0","summary":"RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $36 from $20 and keeps an Outperform rating on the shares. Following ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-36-from-20-at-rbc-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-36-from-20-at-rbc-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"gpt_icon":0},{"id":"2605140183","title":"Definium Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605140183","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605140183?lang=en_us&edition=fundamental","pubTime":"2026-01-23 23:27","pubTimestamp":1769182020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2026 10:27 ET (15:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"gpt_icon":0},{"id":"2605470591","title":"RBC Raises Price Target on Definium Therapeutics to $36 From $20, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2605470591","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605470591?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:52","pubTimestamp":1769172747,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) has an average rating of buy and mean price target of $30, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DFTX"],"gpt_icon":0},{"id":"2605117138","title":"Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry","url":"https://stock-news.laohu8.com/highlight/detail?id=2605117138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605117138?lang=en_us&edition=fundamental","pubTime":"2026-01-21 00:07","pubTimestamp":1768925273,"startTime":"0","endTime":"0","summary":"Definium Therapeutics ( ($DFTX) ) has shared an announcement. Definium Therapeutics has launched “Rerouting Minds,” an educational campaign designe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-launches-educational-lsd-campaign-to-advance-psychedelic-psychiatry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-launches-educational-lsd-campaign-to-advance-psychedelic-psychiatry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2604911557","title":"Definium Therapeutics: Advancing Late-Stage Psychedelic Pipeline and Diversifying Assets Underpin Buy Rating and $61 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2604911557","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604911557?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:06","pubTimestamp":1768914414,"startTime":"0","endTime":"0","summary":"Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Definium Therapeutics. The associated price target remains the same with $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-advancing-late-stage-psychedelic-pipeline-and-diversifying-assets-underpin-buy-rating-and-61-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-advancing-late-stage-psychedelic-pipeline-and-diversifying-assets-underpin-buy-rating-and-61-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","SSI"],"gpt_icon":0},{"id":"2602512636","title":"Mind Medicine rebrands to Definium Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512636?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:11","pubTimestamp":1768219919,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, formerly Mind Medicine (MNMD), unveiled its new brand. In conjunction with the rebrand, the company’s Nasdaq ticker symbol w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-rebrands-to-definium-therapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-rebrands-to-definium-therapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4547","BK4007","NQmain","BK4539","BK4139","MNMD","DFTX"],"gpt_icon":0},{"id":"2602147475","title":"Mind Medicine (MindMed) Inc: Company Shares Will Trade Under New Nasdaq Ticker Symbol \"Dftx\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2602147475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602147475?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:08","pubTimestamp":1768219687,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0PN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MNMD","DFTX","BK4547"],"gpt_icon":0},{"id":"2602351196","title":"MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2602351196","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602351196?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:41","pubTimestamp":1768218118,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. has highlighted progress across its therapeutic pipeline, with three Phase 3 clinical trial readouts anticipated in 2026 for the treatment of generalized anxiety disorder  and major depressive disorder . The company emphasizes the significant unmet need in psychiatry due to limited and recycled treatment options for anxiety and depressive disorders, which affect over 50 million people and are growing at an annual rate of over 5%. Recent Phase 2b studies demonstrated a statistically significant dose response, supporting 100 g as the optimal dose for further development. The findings suggest the results are robust and unlikely to be explained by functional unblinding. MindMed is advancing multiple product candidates, including lysergide tartrate for MDD and DT4022  for autism spectrum disorder, through various stages of clinical development. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7hzFnH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4007","DFTX","MNMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com","stockEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.25},{"period":"3month","weight":0.4918},{"period":"6month","weight":0.8054},{"period":"1year","weight":1.1069},{"period":"ytd","weight":0.2957}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.1431},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.13566},{"month":3,"riseRate":0.25,"avgChangeRate":0.069329},{"month":4,"riseRate":0.75,"avgChangeRate":0.007711},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002468},{"month":6,"riseRate":0.4,"avgChangeRate":-0.111207},{"month":7,"riseRate":0.8,"avgChangeRate":0.20763},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction